HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection. 2019

Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Metabiota, San Francisco, CA, USA.

BACKGROUND Lassa virus (LASV) is the etiologic agent of an acute hemorrhagic fever endemic in West Africa. Natural killer (NK) cells control viral infections in part through the interaction between killer cell immunoglobulin-like receptors (KIRs) and their ligands. LASV infection is associated with defective immune responses, including inhibition of NK cell activity in the presence of MHC-class 1+-infected target cells. METHODS We compared individual KIR and HLA-class 1 genotypes of 68 healthy volunteers to 51 patients infected with LASV in Sierra Leone, including 37 survivors and 14 fatalities. Next, potential HLA-C1, HLA-C2, and HLA-Bw4 binding epitopes were in silico screened among LASV nucleoprotein (NP) and envelope glycoprotein (GP). Selected 10-mer peptides were then tested in peptide-HLA stabilization, KIR binding and polyfunction assays. RESULTS LASV-infected patients were similar to healthy controls, except for the inhibitory KIR2DL2 gene. We found a specific increase in the HLA-C1:KIR2DL2 interaction in fatalities (10/11) as compared to survivors (12/19) and controls (19/29). We also identified that strong of NP and GP viral epitopes was only observed with HLA-C molecules, and associated with strong inhibition of degranulation in the presence of KIR2DL+ NK cells. This inhibitory effect significantly increased in the presence of the vGP420 variant, detected in 28.1% of LASV sequences. CONCLUSIONS Our finding suggests that presentation of specific LASV epitopes by HLA-C alleles to the inhibitory KIR2DL2 receptor on NK cells could potentially prevent the killing of infected cells and provides insights into the mechanisms by which LASV can escape NK-cell-mediated immune pressure.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007835 Lassa Fever An acute febrile human disease caused by the LASSA VIRUS. Lassa Virus Infection,Fever, Lassa,Infection, Lassa Virus,Lassa Fevers,Lassa Virus Infections,Virus Infection, Lassa
D007836 Lassa virus A species of ARENAVIRUS, part of the Old World Arenaviruses (ARENAVIRUSES, OLD WORLD), and the etiologic agent of LASSA FEVER. LASSA VIRUS is a common infective agent in humans in West Africa. Its natural host is the multimammate mouse Mastomys natalensis.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic

Related Publications

Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
September 2006, Journal of virology,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
December 2008, Journal of virology,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
April 2016, European journal of immunology,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
November 2015, PLoS medicine,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
December 2018, Journal of infection in developing countries,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
April 2005, Journal of virology,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
April 2004, Blood,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
November 2016, Cell reports,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
May 2016, Vaccine,
Nadia Wauquier, and Caroline Petitdemange, and Nadine Tarantino, and Christopher Maucourant, and Moinya Coomber, and Victor Lungay, and James Bangura, and Patrice Debré, and Vincent Vieillard
August 2015, The Journal of general virology,
Copied contents to your clipboard!